Robert W. Baird Reiterates “Sell” Rating for Theravance Biopharma, Inc. (TBPH)

Theravance Biopharma, Inc. (NASDAQ:TBPH)‘s stock had its “sell” rating reissued by Robert W. Baird in a research report issued on Wednesday. They currently have a $22.00 price objective on the biopharmaceutical company’s stock. Robert W. Baird’s price objective suggests a potential downside of 23.53% from the company’s current price.

Other equities research analysts have also issued research reports about the stock. Cantor Fitzgerald set a $55.00 price objective on shares of Theravance Biopharma and gave the company a “buy” rating in a research note on Wednesday, October 25th. Zacks Investment Research raised shares of Theravance Biopharma from a “sell” rating to a “hold” rating and set a $37.00 price objective for the company in a research note on Tuesday, October 10th. ValuEngine lowered shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. Evercore ISI started coverage on shares of Theravance Biopharma in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $45.00 price objective for the company. Finally, BidaskClub lowered shares of Theravance Biopharma from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 2nd. Four investment analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. Theravance Biopharma has a consensus rating of “Hold” and an average price target of $41.86.

TRADEMARK VIOLATION WARNING: This piece was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at https://www.com-unik.info/2017/11/03/robert-w-baird-reiterates-sell-rating-for-theravance-biopharma-inc-tbph.html.

In other Theravance Biopharma news, EVP Bradford J. Shafer sold 14,670 shares of the business’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $30.77, for a total transaction of $451,395.90. Following the completion of the transaction, the executive vice president now owns 134,327 shares of the company’s stock, valued at approximately $4,133,241.79. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Frank Pasqualone bought 4,000 shares of the business’s stock in a transaction on Monday, August 21st. The shares were purchased at an average cost of $26.34 per share, with a total value of $105,360.00. Following the transaction, the senior vice president now owns 213,180 shares in the company, valued at $5,615,161.20. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 20,000 shares of company stock valued at $494,300. Company insiders own 6.10% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the business. Parametric Portfolio Associates LLC lifted its position in Theravance Biopharma by 1.5% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 14,307 shares of the biopharmaceutical company’s stock worth $570,000 after acquiring an additional 217 shares during the last quarter. Ameritas Investment Partners Inc. lifted its position in Theravance Biopharma by 6.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,865 shares of the biopharmaceutical company’s stock worth $153,000 after acquiring an additional 230 shares during the last quarter. SG Americas Securities LLC lifted its position in Theravance Biopharma by 8.1% during the 2nd quarter. SG Americas Securities LLC now owns 5,931 shares of the biopharmaceutical company’s stock worth $236,000 after acquiring an additional 443 shares during the last quarter. Legal & General Group Plc lifted its position in Theravance Biopharma by 3.7% during the 2nd quarter. Legal & General Group Plc now owns 16,289 shares of the biopharmaceutical company’s stock worth $649,000 after acquiring an additional 576 shares during the last quarter. Finally, Zacks Investment Management lifted its position in Theravance Biopharma by 4.6% during the 2nd quarter. Zacks Investment Management now owns 21,603 shares of the biopharmaceutical company’s stock worth $861,000 after acquiring an additional 959 shares during the last quarter. 84.86% of the stock is owned by hedge funds and other institutional investors.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

What are top analysts saying about Theravance Biopharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Theravance Biopharma Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit